THDBH110 + THDBH111

THDBH110 + THDBH111 is a drug development program by Tonghua Dongbao Pharmaceutical (Dongbao Pharmaceutical) targeting type 2 diabetes in adults. THDBH110 is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed to mimic the action of the incretin hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying to improve glycemic control. While THDBH110 has entered Phase I clinical testing as of late 2023, THDBH111 is frequently listed alongside it in company pipelines, potentially representing a related compound or a component of a combination strategy. The program aims to provide an oral alternative to injectable GLP-1 therapies.